10.JPG)
In-Silico Drug Discovery Market Size is valued at USD 10.9 Bn in 2023 and is predicted to reach USD 40.3 Bn by the year 2031 at a 18.05% CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The growing emphasis on minimizing prescription errors, technological developments in computational biology, and the expanding usage of cloud-based technologies in drug discovery are driving the industry.
- The global in-silico drug discovery industry is propelled by rapid technology breakthroughs in computational biology and the development of new pharmacological compounds.
- North America dominated the market and accounted for a global revenue share in 2023.
- In the in-silico drug discovery market, preclinical tests accounted for the greatest share. Preclinical trials are being undertaken at an increasing rate due to a number of factors, including the desire for more effective medicines, the complexity of diseases becoming more complex, and regulatory restrictions.
In-silico drug discovery approaches can aid in the identification of therapeutic targets. The approaches can also examine potential binding active areas in the target structures. Using computational approaches and computers permeates all parts of drug research and design. These techniques are making it easier to enter the vast amounts of data being produced and to evaluate the complicated biological data involved to gain insights that can be used in the drug discovery process. These computational techniques can potentially speed up and reduce the cost of delivering potential new medication candidates.
The in-silico drug design process has applications throughout the entire drug development process. These techniques help choose the most effective lead molecule, which can save time and money by avoiding costly setbacks in the later stages of clinical testing. Furthermore, developing new pharmaceutical molecules and rapid technological advancements in computational biology drive the global in-silico drug discovery industry. These advancements have facilitated the data processing and analysis phases of sequencing, shortened turnaround time and improved accuracy.
However, the market growth is hampered by the lack of knowledge of the safety and health of the in-silico drug discovery market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity in-silico drug discovery, the technology's analysis timescales are substantial independent of the size of the stimulated systems, ranging from tens to hundreds of nanoseconds. Unfortunately, it is sometimes impossible to determine protein folding in such a short period, ranging from milliseconds to seconds. The in-silico drug discovery market is expected to be propelled throughout the forecast period by technical advances, strong vendors, and a huge patient population suffering from serious diseases. A variety of chronic and infectious diseases, such as COVID-19 and chronic kidney disease, and an improving healthcare infrastructure are receiving a growing amount of attention.
Competitive Landscape
Some Major Key Players In The In-Silico Drug Discovery Market:
- Aragen Life Sciences Pvt. Ltd.
- Curia Global, Inc.
- Certara, USA.
- Charles River
- Chemical Computing Group ULC.
- Collaborative Drug Discovery Inc.
- Dassault Systemes
- e-therapeutics plc.
- Evotec
- Insilico Medicine
- Ligand Pharmaceuticals Incorporated
- Numerate, Inc.
- PerkinElmer Inc.
- Schrödinger, Inc.
- Selvita
- Simulations Plus
- Tracxn Technologies
- WuXi AppTec
- Others
Market Segmentation:
The in-silico drug discovery market is segmented based on workflow, products, technology, software and end users. As per the workflow, the market is segmented into discovery, pre-clinical tests, and clinical trials. By products, the market is segmented into software, software-as-a-service (SaaS), and consultancy-as-a-service. By technology, the market is segmented into artificial intelligence, graphics processing units (GPUs), and other technologies. By software, the market is segmented into molecular modelling de novo drug design software and pharmacophore modelling software. By end user, the market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, academic and research institutes, and others.
Based On The Products, The Software-As-A-Service (SAAS) In-Silico Drug Discovery Market Segment Is A Major Contributor To The In-Silico Drug Discovery Market.
The software-as-a-service (SaaS) in-silico drug discovery market is expected to lead with a major global market share in 2022. Businesses can save money by switching to software-as-a-service (SaaS) since there is no need to purchase and install software on each employee's computer, the service can grow as the company does, it can be integrated with other programs, and updates are distributed instantly to all users.
Graphics Processing Unit (GPU) Segment To Witness Growth At A Rapid Rate.
The graphics processing unit (GPU) makes up the bulk of in-silico drug discovery because GPU can significantly improve a computer's processing speed and efficiency. Accelerating the processing of technical and scientific data, GPUs are increasingly being used in tandem with CPUs to boost performance, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American In-Silico Drug Discovery Market Holds A Significant Revenue Share.
The North American in-silico drug discovery market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high demand for therapies for diseases with low prevalence, such as cystic fibrosis and ALS. The industry is growing because the infrastructure connecting suppliers and distributors is more advanced in this area than in any other. In addition, Asia Pacific is estimated to grow rapidly in the global in-silico drug discovery market because of the increasing patient population with diseases, both chronic and infectious and other conditions, and a growing government focus on strengthening healthcare infrastructure are all factors pushing the market forward.
Recent Developments:
- In May 2023, FAR Biotech and Aragen Life Sciences initiated a collaborative effort to progress the neurodegeneration preclinical program. Aragen has been selected to furnish integrated drug discovery (IDD) services to bolster FAR Biotech's quantum biomodelling approach.
- In June 2022, Certara introduced the Simcyp Discovery Simulator, an innovative software specifically developed for scientists engaged in translational research and small-molecule drug discovery. Utilizing physiologically based pharmacokinetic (PBPK) modelling and simulation, Simcyp Discovery, which was derived from the industry-leading Simcyp Simulator, bolstered confidence in early-stage development decisions.
In-Silico Drug Discovery Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 10.9 Bn |
|
Revenue Forecast In 2031 |
USD 40.3 Bn |
|
Growth Rate CAGR |
CAGR of 18.05% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, By Workflow, By Technology, By Software Type, By End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Aragen Life Sciences Pvt. Ltd., Curia Global, Inc., Certara, USA., Charles River, Chemical Computing Group ULC., Collaborative Drug Discovery Inc., Dassault Systemes, e-therapeutics plc., Evotec, Insilico Medicine, Ligand Pharmaceuticals Incorporated, Numerate, Inc., PerkinElmer Inc., Schrödinger, Inc., Selvita, Simulations Plus, Tracxn Technologies, WuXi AppTec. And others. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
